Mwita Julius Chacha, Francis Joel M, Omech Bernard, Botsile Elizabeth, Oyewo Aderonke, Mokgwathi Matshidiso, Molefe-Baikai Onkabetse Julia, Godman Brian, Tshikuka Jose-Gaby
Internal Medicine, University of Botswana, Gaborone, Botswana
Internal Medicine, Princess Marina Hospital, Gaborone, Botswana.
BMJ Open. 2019 Jul 23;9(7):e026807. doi: 10.1136/bmjopen-2018-026807.
Control of glycaemic, hypertension and low-density lipoprotein-cholesterol (LDL-C) among patients with type 2 diabetes mellitus (T2DM) is vital for the prevention of cardiovascular diseases. The current study was an audit of glycaemic, hypertension and LDL-C control among ambulant patients with T2DM in Botswana. Also, the study aimed at assessing factors associated with attaining optimal glycaemic, hypertension and LDL-C therapeutic goals.
A cross-sectional study.
A specialised public diabetes clinic in Gaborone, Botswana.
Patients with T2DM who had attended the clinic for ≥3 months between August 2017 and February 2018.
The proportion of patients with optimal glycaemic (HbA1c<7%), hypertension (blood pressure <140/90 mm Hg) and LDL-C (<1.8 mmol/L) control.
The proportions of patients meeting optimal targets were 32.3% for glycaemic, 54.2% for hypertension and 20.4% for LDL-C. Age≥ 50 years was positively associated with optimal glycaemic control (adjusted OR [AOR] 5.79; 95% CI 1.08 to 31.14). On the other hand, an increase in diabetes duration was inversely associated with optimal glycemic control (AOR 0.91; 95% CI 0.85 to 0.98). Being on an ACE inhibitor was inversely associated with optimal hypertension control (AOR 0.35; 95% CI 0.14 to 0.85). Being female was inversely associated with optimal LDL-C control (AOR 0.24; 95% CI (0.09 - 0.59).
Patients with T2DM in Gaborone, Botswana, presented with suboptimal control of recommended glycaemic, hypertension and LDL-C targets. These findings call for urgent individual and health systems interventions to address key determinants of the recommended therapeutic targets among patients with diabetes in this setting.
控制2型糖尿病(T2DM)患者的血糖、血压和低密度脂蛋白胆固醇(LDL-C)水平对于预防心血管疾病至关重要。本研究对博茨瓦纳门诊T2DM患者的血糖、血压和LDL-C控制情况进行了审核。此外,该研究旨在评估与实现最佳血糖、血压和LDL-C治疗目标相关的因素。
横断面研究。
博茨瓦纳哈博罗内的一家专门的公立糖尿病诊所。
2017年8月至2018年2月期间在该诊所就诊≥3个月的T2DM患者。
血糖控制最佳(糖化血红蛋白<7%)、血压控制最佳(血压<140/90 mmHg)和LDL-C控制最佳(<1.8 mmol/L)的患者比例。
血糖控制达最佳目标的患者比例为32.3%,血压控制达最佳目标的患者比例为54.2%,LDL-C控制达最佳目标的患者比例为20.4%。年龄≥50岁与最佳血糖控制呈正相关(校正比值比[AOR] 5.79;95%可信区间1.08至31.14)。另一方面,糖尿病病程延长与最佳血糖控制呈负相关(AOR 0.91;95%可信区间0.85至0.98)。使用血管紧张素转换酶抑制剂与最佳血压控制呈负相关(AOR 0.35;95%可信区间0.14至0.85)。女性与最佳LDL-C控制呈负相关(AOR 0.24;95%可信区间[0.09 - 0.59])。
博茨瓦纳哈博罗内的T2DM患者在推荐的血糖、血压和LDL-C目标控制方面未达最佳。这些发现呼吁采取紧急的个人和卫生系统干预措施,以解决该环境下糖尿病患者推荐治疗目标的关键决定因素。